Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Additional Information (Detail)

v3.10.0.1
Fair Value Measurements - Additional Information (Detail) - USD ($)
 5 Months Ended 9 Months Ended
Mar. 15, 2018
Sep. 30, 2018
Aug. 15, 2018
Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Investment Owned, at Fair Value   $ 6,675,000   $ 1,985,000
Working Capital Note Convertible To Equity   0    
Common Stock Redemption Price Per Share     $ 11.00  
Helocyte [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value   0   $ 87,000
Debt Conversion, Converted Instrument, Amount   0    
Origo Acquisition Corporation [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Investment Owned, at Fair Value   1,400,000    
Working Capital Note Convertible To Equity   $ 300,000    
National Holdings Corporation [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Percentage of Outstanding Stock To Be Issued Upon Exercise of Warrants 44.00%      
Warrants Not Settleable in Cash, Fair Value Disclosure $ 13,600,000